XELIRI compared with FOLFIRI as a secondline treatment in patients with metastatic colorectal cancer

By                  

Oncology Letters, Vol. 8, Iss. 4, 2014-01 ,pp. : 1864-1872

Spandidos Publications

Access to resources Recommend Favorite

Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer

By Alonso V.   Escudero P.   Zorrilla M.   Isla M.D.   Herrero A.   Mayordomo J.I.   Martinez-Trufero J.   Saenz A.   Tres A.   Anton A.  

European Journal of Cancer, Vol. 37, Iss. 18, 2001-12 ,pp. : 2385-2391

Elsevier

Access to resources Recommend Favorite

Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer

By Cassinello J.   López-Alvarez P.   Martínez-Guisado A.   Valladares M.   Huidobro G.   López R.   Bohn U.   Sevilla I.   Ballesteros P.   Jorge M.   Pérez-Carrión R.   Fernández J.   Dorta J.  

Medical Oncology, Vol. 20, Iss. 1, 2003-03 ,pp. : 37-43

Humana Press, Inc

Access to resources Recommend Favorite

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

By Sørbye Halfdan   Berglund Åke   Tveit Kjell Magne   Øgreid Dagfinn   Wanderås Eva Hoff   Wentzel-Larsen Tore   Dahl Olav   Glimelius Bengt  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 982-988

Informa Healthcare

Access to resources Recommend Favorite

Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens

By                    

Oncology Letters, Vol. 2, Iss. 2, 2011-01 ,pp. : 247-251

Spandidos Publications

Access to resources Recommend Favorite